BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang T, Wang T, You F, Li Z, Chen D, Zhang K, Tian S, Sheng B, Wu H, Jiang L, Ma R, An G, Meng H, Yang L. Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia. Transpl Immunol 2022;:101538. [PMID: 35051588 DOI: 10.1016/j.trim.2022.101538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yong Joon Kim J, Sang Z, Xiang Y, Shen Z, Shi Y. Nanobodies: Robust miniprotein binders in biomedicine. Adv Drug Deliv Rev 2023;195:114726. [PMID: 36754285 DOI: 10.1016/j.addr.2023.114726] [Reference Citation Analysis]
2 Silva G, Rodrigues AF, Ferreira S, Matos C, Eleutério RP, Marques G, Kucheryava K, Lemos AR, Sousa PMF, Castro R, Barbas A, Simão D, Alves PM. Novel scFv against Notch Ligand JAG1 Suitable for Development of Cell Therapies toward JAG1-Positive Tumors. Biomolecules 2023;13:459. [DOI: 10.3390/biom13030459] [Reference Citation Analysis]
3 Maali A, Gholizadeh M, Feghhi-Najafabadi S, Noei A, Seyed-Motahari SS, Mansoori S, Sharifzadeh Z. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer. Front Immunol 2023;14:1012841. [PMID: 36761751 DOI: 10.3389/fimmu.2023.1012841] [Reference Citation Analysis]
4 Poustforoosh A, Faramarz S, Negahdaripour M, Hashemipour H. Modeling and affinity maturation of an anti-CD20 nanobody: a comprehensive in-silico investigation. Sci Rep 2023;13:582. [PMID: 36631511 DOI: 10.1038/s41598-023-27926-4] [Reference Citation Analysis]
5 Huan T, Li H, Tang B. Radiotherapy plus CAR-T cell therapy to date: A note for cautions optimism? Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1033512] [Reference Citation Analysis]
6 Zeng Q, Liu Z, Niu T, He C, Qu Y, Qian Z. Application of nanotechnology in CAR-T-cell immunotherapy. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.107747] [Reference Citation Analysis]